Global Antibacterial Pull Incentives Show Divergent Criteria, Potentially Fragmenting Drug Development
A new analysis published in *The Lancet Regional Health – Europe* reveals significant inconsistencies in the eligibility and evaluation criteria of 'pull incentives' launched by governments across the UK, Sweden, Germany, France, Italy, the United States, Japan, and the European Union. These incentives are designed to stimulate the development of new antibacterial drugs. The study, led by Michael Anderson and Elias Mossialos of the London School of Economics and Political Science, is the first systematic comparison of these schemes. Researchers found that while all nine implemented incentives require products to target high-priority medical needs, criteria for relative effectiveness, innovative characteristics, and company-level obligations like stewardship, patient access, and environmental safeguards vary widely. This patchwork approach, researchers warn, may send confused signals to pharmaceutical developers and fragment the global response to drug-resistant infections. 
